Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 8/2017

01.08.2017 | Neuro-oncology (S Nagpal, Section Editor)

Tumor Treating Fields in Neuro-Oncological Practice

verfasst von: Maciej M. Mrugala, Jacob Ruzevick, Piotr Zlomanczuk, Rimas V. Lukas

Erschienen in: Current Oncology Reports | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Electric fields are known to produce biological effects. Depending on specific frequency, they can stimulate healing, directly damage tissues, or produce anti-mitotic activity. Frequencies of 100–300 KHz have been shown to disrupt mitosis and lead to cellular death. Growth of cancer cell lines, both in vitro and in vivo, was shown to be inhibited by application of the electric fields. In the clinical setting, electric fields are available for treatment of brain tumors, specifically glioblastoma (GBM), through a portable device producing so-called tumor treating fields (TTF). Clinical trials conducted in patients with recurrent and newly diagnosed GBM indicated that this novel treatment modality is active and associated with minimal toxicity. This manuscript will review the available evidence supporting the use of TTF in neuro-oncologic practice.
Literatur
1.
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.CrossRefPubMed
2.
Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.CrossRefPubMed
3.
Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572–8.CrossRefPubMed
4.
Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–40.CrossRefPubMed
5.
Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722–9.CrossRefPubMed
6.
Ahmed R, Oborski MJ, Hwang M, et al. Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag Res. 2014;6:149–70.PubMedPubMedCentral
7.
Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253–9.CrossRefPubMed
8.
Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740–5.CrossRefPubMed
9.
•• Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48:2192–202. Pivotal clinical trial using TTF in patients with recurrent GBM, showing that this modality provides similar outcomes (PFS and OS) but with less toxicity than chemotherapy. CrossRefPubMed
10.
Kirson ED, Dbalý V, Tovarys F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007;104:10152–7.CrossRefPubMedPubMedCentral
11.
Kirson ED, Schneiderman RS, Dbalý V, et al. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med Phys. 2009;9:1.CrossRefPubMedPubMedCentral
12.
•• Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314:2535–43. This is the first randomized phase III study with TTF technology in combination with chemotherapy in newly diagnosed patients with GBM. The study showed that addition of TTF to standard of care (temozolomide) significantly improves PFS and OS. CrossRefPubMed
13.
Kirson ED, Wasserman Y, Izhaki A, et al. Modeling tumor growth kinetics and its implications for TTFields treatment planning. The 2010 Society of Neuro-Oncology Scientific Meeting and Education Day, Montreal, Canada. Soc Neuro-Oncol. 2010;12(Suppl 4):1–148.
14.
• Mrugala MM, Engelhard HH, Dinh Tran D, et al. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: the Patient Registry Dataset (PRiDe). Semin Oncol. 2014;41(Suppl 6):S4–S13. This registry shows the feasibility of using TTF therapy in real clinical setting. While retrospective, it provides insights into important factors that might influence better outcomes in recurrent GBM patients such as compliance with therapy, treatment at first recurrence, and the patient’s performance status. CrossRefPubMed
15.
Kanner AA, Wong ET, Villano JL, Ram Z, EF-11 Investigators. Post hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician’s choice chemotherapy. Semin Oncol. 2014;41(Suppl 6):S25–34.CrossRefPubMed
16.
Swanson KD, Lok E, Wong ET. An overview of alternating electric fields therapy (NovoTTF Therapy) for the treatment of malignant glioma. Curr Neurol Neurosci Rep. 2016;16:8–10.CrossRefPubMedPubMedCentral
17.
Rehman AA, Elmore KB, Mattei TA. The effects of alternating electric fields in glioblastoma: current evidence on therapeutic mechanisms and clinical outcomes. Neurosurg Focus. 2015;38:E14.CrossRefPubMed
18.
Kirson ED, Gurvich Z, Schneiderman R, et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004;64:3288–95.CrossRefPubMed
19.
• Miranda PC, Mekonnen A, Salvador R, Basser PJ. Predicting the electric field distribution in the brain for the treatment of glioblastoma. Phys Med Biol. 2014;59:4137–47. This paper focuses on important physical properties of the electric fields used in therapy of GBM. It helps to understand the concept of electric field distribution within the brain and the tumor with practical implications for the clinician. CrossRefPubMedPubMedCentral
20.
Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors. Onkologie. 2008;31:362–5.CrossRefPubMed
21.
Pless M, Droege C, Moos von R, et al. A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung Cancer. 2013;81:445–50.CrossRefPubMed
22.
Kanner AA, Wong ET, Villano JL, et al. Investigators: NO-065. Tumor treating fields (TTFields) in recurrent GBM. An updated subgroup analysis of the phase III data. Soc Neuro-Oncol.
23.
Ram Z, Wong ET, Gutin PH. Comparing the effect of NovoTTF to bevacizumab in recurrent GBM: a post-hoc subanalysis of the phase III trial data. Neuro-Oncology. 2011; 13.
24.
Giladi M, Weinberg U, Schneiderman RS, et al. Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo. Semin Oncol. 2014;41(Suppl 6):S35–41.CrossRefPubMed
25.
Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer. 2008;113:405–10.CrossRefPubMed
26.
Wong ET, Phung M, Barron L, et al. Updated safety analysis of bevacizumab plus alternating electric fields therapy in patients with recurrent malignant gliomas. Neuro-Oncology. 2015;17(Suppl 5):v174.PubMedCentral
27.
Mrugala MM, Graham CA, Rockhill JK, Silbergeld DL. NOVO-TTF 100A System used successfully in a patient with a ventriculo-peritoneal shunt. Neuro-Oncology. 2014;16(Suppl 2):ii101.
28.
Raizer JJ, Fitzner KA, Jacobs DI, et al. Economics of malignant glioma: a critical review. J Oncol Prac. 2015;11(1):e59–65.CrossRef
29.
Lacouture ME, Davis ME, Elzinga G, et al. Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma. Semin Oncol. 2014;41(Suppl 4):S1–14.CrossRefPubMed
Metadaten
Titel
Tumor Treating Fields in Neuro-Oncological Practice
verfasst von
Maciej M. Mrugala
Jacob Ruzevick
Piotr Zlomanczuk
Rimas V. Lukas
Publikationsdatum
01.08.2017
Verlag
Springer US
Erschienen in
Current Oncology Reports / Ausgabe 8/2017
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-017-0611-8

Weitere Artikel der Ausgabe 8/2017

Current Oncology Reports 8/2017 Zur Ausgabe

Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Current Management Strategy for Penile Cancer and Future Directions

Gynecologic Cancers (NS Reed, Section Editor)

Early Cervical Cancer: Current Dilemmas of Staging and Surgery

Cardio-oncology (EH Yang, Section Editor)

Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts

Breast Cancer (B Overmoyer, Section Editor)

Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data

Lung Cancer (JM Johnson, Section Editor)

The Role of Telemedicine in Providing Thoracic Oncology Care to Remote Areas of British Columbia

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise